Although Enbrel Remains the Most Commonly Used Biologic for Psoriasis, Patient Share for Humira Continues to Climb

Decision Resources Unveils New Online Platform for Its Treatment Algorithms Service

BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one of the world’s leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that although Amgen/Pfizer/Stiefel’s Enbrel remains the most commonly used biologic for the treatment of psoriasis, patient share for Abbott’s Humira continues to climb. According to Treatment Algorithms in Psoriasis, Humira’s patient share among recently treated patients rose from 7.9 percent in the first quarter of 2010 to 8.8 percent in the fourth quarter. Meanwhile, Enbrel’s patient share in the first three quarters of 2010 varied from 11 to 11.3 percent and fell to 10.4 percent in the fourth quarter of 2010.

“Enbrel remains the leading biologic for the treatment of psoriasis, however, this position is vulnerable due to increasing competition among biologics,” said Decision Resources Analyst Iva Holder, Ph.D. “While Enbrel’s success reflects physicians’ comfort with its long-standing safety record, its declining patient share in the fourth quarter of 2010 is likely due in part to patients’ and physicians’ growing preference for Humira, which is more effective and has a more convenient dosing schedule.”

The analysis also finds that patient share of Janssen Biotech’s Stelara in recently treated patients nearly doubled from 0.8 percent in the first quarter of 2010 to 1.5 percent in the fourth quarter of 2010. Stelara was the most recent biologic to gain approval from the U.S. Food and Drug Administration for the treatment of moderate-to-severe psoriasis, in September 2009.

“Physician inexperience with Stelara’s novel mechanism of action and its limited long-term safety data have been major factors restraining Stelara’s penetration in the psoriasis market,” added Dr. Holder. “Yet, the degree of steady increase in Stelara prescriptions in 2010 suggests that physicians are becoming increasingly comfortable with its clinical profile.”

Enhanced Service and Platform Now Available

The analysis is part of Decision Resources’ enhanced Treatment Algorithms series, which features a new online platform. Interactive, user-friendly and with more graphical data views, the new platform enables users to easily toggle between diseases and time cohorts, which ultimately allows for more in-depth analysis on each line of therapy. Treatment Algorithms analysis is now updated quarterly to provide ongoing trending of product utilization by line of therapy and new therapy initiations. Through examination of patient-level claims data, Decision Resources’ Treatment Algorithms series provides exceptional insight into physicians’ prescribing trends and the factors that drive therapy choice, from diagnosis through multiple courses of treatment, for a specific disease.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.



CONTACT:

Decision Resources
Lisa Osgood, 781-993-2606
[email protected]
or
Decision Resources, Inc.
Christopher Comfort, 781-993-2597
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.